Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

662
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
662
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Drug Therapy01:28

Drug Therapy

401
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
401
The Placebo Effect01:54

The Placebo Effect

7.1K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
7.1K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.2K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.2K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.4K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

B cell-derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathy.

Kidney international·2025
Same author

Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.

The Cochrane database of systematic reviews·2022
Same author

Evaluation of actions, barriers, and facilitators to reducing dietary sodium in health care institutions.

Food science & nutrition·2018
Same author

Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).

The Cochrane database of systematic reviews·2018
Same author

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.

Heart (British Cardiac Society)·2017
Same author

De-escalation techniques for psychosis-induced aggression or agitation.

The Cochrane database of systematic reviews·2017

Related Experiment Video

Updated: Mar 29, 2026

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
12:00

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

Published on: November 19, 2014

13.4K

Zuclopenthixol versus placebo for schizophrenia.

Michael Lacey1, Mahesh B Jayaram

  • 1Department of Psychological Medicine, Humber NHS Foundation Trust, 220-36 Anlaby Road, Hull, UK, HU3 2RW.

The Cochrane Database of Systematic Reviews
|December 2, 2015
PubMed
Summary

Zuclopenthixol dihydrochloride may help schizophrenia symptoms, but evidence is limited and of very low quality. Sedation and some adverse effects were noted compared to placebo, with no data for other formulations.

More Related Videos

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Related Experiment Videos

Last Updated: Mar 29, 2026

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
12:00

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

Published on: November 19, 2014

13.4K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Zuclopenthixol is an established antipsychotic with three formulations: dihydrochloride, acetate, and decanoate.
  • Despite its long-term use, a systematic review comparing its efficacy against placebo in schizophrenia has been lacking.

Purpose of the Study:

  • To systematically review the effectiveness of all zuclopenthixol formulations versus placebo for schizophrenia treatment.

Main Methods:

  • Conducted a comprehensive search of multiple databases and clinical trial registries up to October 2015.
  • Included randomized controlled trials comparing any zuclopenthixol formulation with placebo in schizophrenia patients.
  • Extracted and analyzed data, assessing risk of bias and using GRADE methodology.

Main Results:

  • Only two low-quality studies (65 participants) from 1968-1972 met inclusion criteria, focusing solely on zuclopenthixol dihydrochloride.
  • Zuclopenthixol dihydrochloride showed a statistically significant improvement in global state when assessed by nurses (RR 2.57, 95% CI 1.06 to 6.20), but not psychiatrists.
  • Increased sedation was observed with zuclopenthixol dihydrochloride (RR 4.67, 95% CI 1.23 to 17.68); data on relapse, mental state, and other outcomes were unavailable.

Conclusions:

  • Zuclopenthixol dihydrochloride may offer symptom relief in schizophrenia, supported by limited, very low-quality evidence.
  • Significant sedation and potential adverse effects are associated with zuclopenthixol dihydrochloride.
  • No data exist for zuclopenthixol acetate or decanoate, highlighting a critical gap in evidence for commonly used antipsychotic formulations.